RESUMEN
Great attention is paid to renal cell carcinoma (RCC) due to the growth of its prevalence. This paper is dedicated to the matching of classic clinical and pathological prognostic factors to the character of the expression of proliferation marker Ki-67 in this kind of cancer. The proliferative activity was analyzed in 101 RCC cases by immunohistochemical assays using antibodies to Ki-67. In aggressive RCC and Fuhrman grade 3 to 4 tumors, Ki-67 level was found to be high more often. Besides, time to the appearance of remote metastases was significantly shorter, and total survival rate was significantly lower in RCC with high proliferative activity vs. low.
Asunto(s)
Carcinoma de Células Renales/inmunología , Antígeno Ki-67/inmunología , Neoplasias Renales/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Células Renales/metabolismo , Carcinoma de Células Renales/patología , Proliferación Celular , Femenino , Humanos , Neoplasias Renales/metabolismo , Neoplasias Renales/patología , Masculino , Persona de Mediana Edad , Estudios RetrospectivosRESUMEN
Radical surgery was made in 85 patients with invasive cancer of the bladder. 89.4% patients had the tumor of stage T2-T3. After the operation all 85 patients received 3 courses of adjuvant chemotherapy M-VAC in modification of the Cancer Research Center. The interval between the courses was 3 weeks. The patients were divided into two groups. The test group (n = 43) received surgical treatment, M-VAC chemotherapy and immunocorrection (general magnetotherapy, phytotherapy = cyclopheron). The control group (n = 42) received only surgery and adjuvant chemotherapy. It was found that the above immunocorrection reduces the number of postoperative complications 3.8 times, side effects by chemotherapy by 1.4 times. Absolute count of T lymphocytes and their active forms elevated by 42.8 and 35.7%, respectively, while CIC diminished by 48.8%. The addition of immunocorrection to combined treatment of patients with invasive cancer of the bladder decreased the number of recurrences for 2 years twice. 3-year survival was 1.5 times longer.